[PS4] Presidential Session 4
【E】

[PS4-2] Analysis of the COLLECT Study - Efficacy and Safety of Lenvatinib in Differentiated Thyroid Cancer

^○Hiroyuki Iwasaki¹, Hiroshi Takami², Ito Yasuhiro³, Okamoto Takahiro⁴, Sugitani Iwao⁵, Sugino Kiminori², Takahashi Shunji⁶, Takeyama Hiroshi⁷, Tutui Hidemitsu⁸, Hara Hisato⁹, Mitsuma Ayako¹⁰, Yamashita Hiroyuki¹¹, Ohashi Yasuo¹², Shiroiwa Takeru¹³, Imai Tuneo¹⁴, Tahara Makoto¹⁵ (1.Department of Breast and Endocrine Surgery, Kanagawa Cancer Center, 2.Department of Surgery, Ito Hospital, 3.Department of Clinical Trial, Kuma Hospital, 4.Department of Endocrine Surgery, Tokyo Women's Medical University Hospital, 5.Department of Endocrine Surgery Nippon Medical School Graduate School of Medicine, 6.Department of Medical Oncology, Cancer Institute Hospital of the Japanese Foundation for Cancer Research, 7.Departments of Breast and Endocrine Surgery, The Jikei University School of Medicine, 8.Department of Thoracic and Thyroid Surgery, Tokyo Medical University, 9.Department of Breast and Endocrine Surgery, Faculty of Medicine, University of Tsukuba, 10.Department of Clinical Oncology and Chemotherapy, Nagoya University Hospital, 11.Department of Surgery, Yamashita Thyroid Hospital, 12.Department of Integrated Science and Engineering for Sustainable Society, Chuo University, 13.Center for Outcomes Research and Economic Evaluation for Health, National Institute of Public Health, 14.National Hospital Organization Higashinagoya National Hospital, 15.Department of Head and Neck Medical Oncology, National Cancer Center Hospital East)